JP2017222654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017222654A5 JP2017222654A5 JP2017115935A JP2017115935A JP2017222654A5 JP 2017222654 A5 JP2017222654 A5 JP 2017222654A5 JP 2017115935 A JP2017115935 A JP 2017115935A JP 2017115935 A JP2017115935 A JP 2017115935A JP 2017222654 A5 JP2017222654 A5 JP 2017222654A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- association
- arginine
- arginine amide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- AKGWUHIOEVNNPC-LURJTMIESA-N Arg-OEt Chemical compound CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 claims 3
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 3
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000007979 citrate buffer Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011157654 | 2011-07-19 | ||
| JP2011157654 | 2011-07-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524738A Division JP6176849B2 (ja) | 2011-07-19 | 2012-07-19 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017222654A JP2017222654A (ja) | 2017-12-21 |
| JP2017222654A5 true JP2017222654A5 (cg-RX-API-DMAC7.html) | 2018-02-15 |
| JP6469765B2 JP6469765B2 (ja) | 2019-02-13 |
Family
ID=47558197
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524738A Active JP6176849B2 (ja) | 2011-07-19 | 2012-07-19 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| JP2017115935A Active JP6469765B2 (ja) | 2011-07-19 | 2017-06-13 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524738A Active JP6176849B2 (ja) | 2011-07-19 | 2012-07-19 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9574005B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2735315B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6176849B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013012022A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| EP3062814A1 (en) * | 2013-10-29 | 2016-09-07 | Albumedix A/S | Antibody composition |
| CN106029682B (zh) * | 2013-12-27 | 2021-04-13 | 中外制药株式会社 | 等电点低的抗体的纯化方法 |
| TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| AR104050A1 (es) * | 2015-03-26 | 2017-06-21 | Chugai Pharmaceutical Co Ltd | Proceso de producción con iones de cobre controlados |
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| WO2017057644A1 (ja) * | 2015-09-30 | 2017-04-06 | 持田製薬株式会社 | 高濃度抗体含有液体製剤 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JP7235770B2 (ja) | 2018-05-10 | 2023-03-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| US20200369760A1 (en) * | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| EP3763356A1 (en) * | 2019-07-12 | 2021-01-13 | Ludwig-Maximilians-Universität München | Excipient for biotherapeutics |
| EP4062933A4 (en) * | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| JP2025078889A (ja) * | 2022-02-03 | 2025-05-21 | 天野エンザイム株式会社 | 酵素製剤 |
| WO2025186423A1 (en) | 2024-03-07 | 2025-09-12 | Csl Behring Ag | Immunoglobulin composition and method of generating an aerosol |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| JPS6013718A (ja) | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ワクチン |
| JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| HU218140B (hu) | 1991-04-25 | 2000-06-28 | Chugai Seiyaku Kabushiki Kaisha | Humán interleukin-6-receptorral szembeni átalakított humán antitest |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| JP2942412B2 (ja) | 1991-12-26 | 1999-08-30 | 鐘紡株式会社 | 化粧料 |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK1516628T3 (da) | 1995-07-27 | 2013-09-08 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| CZ106299A3 (cs) | 1996-09-26 | 1999-08-11 | Chugai Seiyaku Kabushiki Kaisha | Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem |
| UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
| SK14812000A3 (sk) | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
| TWI242043B (en) | 2000-03-10 | 2005-10-21 | Chugai Pharmaceutical Co Ltd | Polypeptide inducing apoptosis |
| PT1314437E (pt) | 2000-08-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Preparações estabilizadas contendo anticorpo |
| AU1091702A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded tpo agonist antibody |
| EP1391209A4 (en) | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
| EP1475101B1 (en) | 2002-02-14 | 2010-10-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
| JP4083634B2 (ja) | 2002-07-11 | 2008-04-30 | 旭化成ファーマ株式会社 | 光に安定なカルシトニン水溶液 |
| JP3976257B2 (ja) | 2002-09-17 | 2007-09-12 | 栄研化学株式会社 | 蛋白質の安定化方法 |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
| EP1908482B1 (en) * | 2005-06-10 | 2017-09-06 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| US20080071063A1 (en) * | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| JP2007332093A (ja) * | 2006-06-16 | 2007-12-27 | Apro Life Science Institute Inc | タンパク質のリフォールディング添加剤及びそれを用いたタンパク質の再生方法 |
| AU2008204901A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
| EP2068923A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
| JP5119545B2 (ja) * | 2007-06-19 | 2013-01-16 | 国立大学法人 筑波大学 | 蛋白質を含む液状組成物中における蛋白質の安定化方法 |
| WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| BRPI0817250A2 (pt) | 2007-09-26 | 2014-06-17 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-receptor da il-6. |
| KR20160074019A (ko) | 2007-12-05 | 2016-06-27 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| WO2009104369A1 (ja) | 2008-02-22 | 2009-08-27 | パナソニック株式会社 | 血漿に含まれる成分の検出方法ならびにそれに用いられる試薬および検出デバイス |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
-
2012
- 2012-07-19 WO PCT/JP2012/068276 patent/WO2013012022A1/ja not_active Ceased
- 2012-07-19 US US14/232,922 patent/US9574005B2/en active Active
- 2012-07-19 EP EP12814155.3A patent/EP2735315B1/en active Active
- 2012-07-19 JP JP2013524738A patent/JP6176849B2/ja active Active
-
2017
- 2017-01-06 US US15/400,355 patent/US10898572B2/en active Active
- 2017-06-13 JP JP2017115935A patent/JP6469765B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017222654A5 (cg-RX-API-DMAC7.html) | ||
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| BR112017008660A2 (pt) | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf | |
| CY1124592T1 (el) | Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| EA201790997A1 (ru) | Композиции гликопептидов | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| MX378502B (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| UA122478C2 (uk) | Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1 | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| BRPI0514340A (pt) | formulações de estabilização | |
| JOP20200140A1 (ar) | صيغ لتركيبات لقاح فيروس حُمى الضنك | |
| EA201890771A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
| JP2019501920A5 (cg-RX-API-DMAC7.html) | ||
| AR093297A1 (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| EA202192568A1 (ru) | Стабилизированные составы, содержащие антитела к il-33 | |
| NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту |